BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab)

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for...

April 17, 2023 | News

AffaMed Therapeutics Approved for Phase 3 Trial of DEXTENZA® in China for Eye Surgery Inflammation and Pain

In addition, AffaMed is pleased to announce that DEXTENZA has recently been approved in Macau, China for the treatment of ocular itchin...

April 17, 2023 | News

Anika Enters Into Cooperation Agreement with Caligan Partners

As part of the agreement, the Company appointed Gary Fischetti as a Class III director. Fischetti will join two existing board members on a newly formed Ca...

April 14, 2023 | News

Evonik wins Asia-Pacific Bioprocessing Excellence Award for Cell Culture Solutions

The Asia-Pacific Bioprocessing Excellence Awards celebrate the latest biopharmaceutical technologies Evonik recognized for high-quality Cell Culture Sol...

April 13, 2023 | News

Discovery Life Sciences Acquiert Reachbio Research Labs

Discovery Life Sciences™ (Discovery), Biospecimen and Biomarker Specialists, has acquired Seattle-based ReachBio Research L...

April 12, 2023 | News

Boan Biotech's Biologics License Application for Boyounuo® (Bevacizumab Injection) Accepted in Brazil

Envisioned to be "a leading global biopharmaceutical company", Boan Biotech develops biologics for both Chinese and international markets, including E...

April 12, 2023 | News

Partnership agreement to commercialize new anti-PD1 antibody in Australia and Southeast Asia signed by Specialised Therapeutics

The therapy ANNIKO® (penpulimab) is an anti-PD1 monoclonal antibody currently under regulatory review by the US FDA for nasopharyngeal carcinoma &...

April 12, 2023 | News

JW Therapeutics' Relma-cel approved for systemic lupus erythematosus trial.

SLE is a complex autoimmune disease with diverse clinical manifestations involving many organs and systems. It is estimated that China has 1 mill...

April 11, 2023 | News

Chinese NMPA Approves Study of Telix Brain Cancer Therapy Candidate

The investigational new drug (IND) application was submitted by Telix's partner in the Greater China region, Grand Pharmaceutical Group Limited (...

April 11, 2023 | News

China's First Nectin-4 Targeted ADC 9MW2821 Clinical Progress Released

Developed with site specific conjugate technology, 9MW2821 is China's first, global second Nectin-4 targeted ADC approved for clinical study. The...

April 08, 2023 | News

Metabolon Launches Targeted Panels to Study Microbiome and Gut Metabolome in Health and Disease

Metabolon, Inc., the global leader in providing metabolomics solutions that advance a wide variety of research, diagnostic, therapeutic development, and pr...

April 05, 2023 | News

Indivumed becomes Indivumed Therapeutics to advance Precision Oncology with Data and AI

After twenty years as one of the first personalized oncology companies, Indivumed today announced its evolution into Indivumed Therapeutics after the acqui...

April 05, 2023 | News

Genome Mapping Takes Center Stage in the Asia Pacific Region

Genome mapping is the process of determining the complete DNA sequence of an organism, including all of its genes and other DNA sequences. The process of g...

April 04, 2023 | Analysis

COVID-19 Infection Shown to Significantly Increase Drug Clearance of Therapeutic Monoclonal Antibodies

Patients with inflammatory diseases being treated with therapeutic monoclonal antibodies (mAbs) such as Infliximab may experience a significant increase in...

April 03, 2023 | News

Stay Connected